scispace - formally typeset
K

Kiyotoshi Kaneko

Researcher at University of California, San Francisco

Publications -  18
Citations -  2532

Kiyotoshi Kaneko is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Scrapie & PrPSc Proteins. The author has an hindex of 16, co-authored 18 publications receiving 2488 citations.

Papers
More filters
Journal ArticleDOI

Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation

TL;DR: The identification of the site at which protein X binds to the cellular isoform of PrP (PrPC) using scrapie-infected mouse (Mo) neuroblastoma cells transfected with chimeric Hu/MoPrP genes even though protein X has not yet been isolated is reported.
Journal ArticleDOI

Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform.

TL;DR: The scrapie prion protein (PrPSc) is the major, and possibly the only, component of the infectious prion; it is generated from the cellular isoform (PrPC) by a conformational change and appears to modulate susceptibility of sheep and humans to prion disease.
Journal ArticleDOI

COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform

TL;DR: It is argued that PrP(Sc) formation is restricted to a specific subcellular compartment and as such, it is likely to involve auxiliary macromolecules found within CLDs.
Journal ArticleDOI

Conformational transitions in peptides containing two putative alpha-helices of the prion protein.

TL;DR: It is suggested that perturbation of the packing environment of the highly conserved residues is a possible mechanism for triggering the conversion of PrPcto PrPsc where α-helices appear to be converted into β-sheets.
Journal ArticleDOI

Mimicking dominant negative inhibition of prion replication through structure-based drug design

TL;DR: Mimicking dominant negative inhibition in the design of drugs that inhibit prion replication may provide a more general approach to developing therapeutics for deleterious protein-protein interactions.